What is the recommended management of scleroderma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Scleroderma Management

Systemic sclerosis (SSc) requires organ-specific pharmacological treatment guided by the 2023 EULAR recommendations, with mycophenolate mofetil as first-line therapy for both skin fibrosis and interstitial lung disease, and combination therapy for pulmonary arterial hypertension. 1

Organ-Based Treatment Algorithm

Skin Fibrosis (Diffuse Cutaneous SSc)

For early, progressive skin involvement:

  • First-line: Mycophenolate mofetil (MMF) - demonstrated mRSS improvement of -4.90 at 24 months 1
  • Alternative first-line options: Methotrexate or rituximab (375 mg/m² weekly x4 weeks showed -6.30 mRSS improvement vs +2.14 placebo) 1
  • Second-line: Tocilizumab may be considered specifically for early, inflammatory dcSSc 1
  • Severe disease (mRSS ≥32): Consider cyclophosphamide or hematopoietic stem cell transplantation 2

The evidence strongly favors MMF over cyclophosphamide due to significantly lower leucopenia rates (4 vs 30 patients) with comparable efficacy 1. Rituximab showed the most dramatic skin improvement in RCT data, though the Japanese dosing regimen differs from standard rheumatologic practice 1.

Interstitial Lung Disease (ILD)

Induction therapy:

  • First-line: Mycophenolate mofetil 1
  • Second-line: Intravenous cyclophosphamide 1
  • Third-line: Rituximab 1

Maintenance therapy:

  • First-line: Mycophenolate mofetil 1
  • Additional option: Nintedanib (particularly for progressive fibrosing ILD) 1

Pulmonary Arterial Hypertension (PAH)

Mild PAH:

  • First-line: PDE5 inhibitors 2
  • Second-line: Endothelin receptor antagonists PLUS PDE5 inhibitors 2
  • Third-line: Prostanoids 2

Severe PAH:

  • First-line: Prostanoids 2
  • Note: 81% expert agreement supports first-line combination therapy for newly diagnosed PAH 1

Raynaud's Phenomenon

Mild RP:

  • First-line: Calcium channel blockers (CCBs) 2
  • Second-line: Add PDE5 inhibitors 2
  • Third-line: Add ARBs or switch to alternative CCB 2

Severe RP (or after third-line failure):

  • Continue CCBs
  • Add PDE5 inhibitors OR prostanoids
  • Consider switching CCB class 2

Non-pharmacological: Avoid cold exposure, use gloves and heating devices, avoid direct contact with cold surfaces 3

Digital Ulcers

Active treatment:

  • First-line: Calcium channel blockers 2
  • Second-line: PDE5 inhibitors 2
  • Local management: Botulinum toxin can be conditionally recommended for refractory/severe DUs 4
  • Surgical option: Autologous adipose tissue grafting when combined with systemic treatments 4

Scleroderma Renal Crisis

Treatment sequence (81% expert agreement):

  • First-line: ACE inhibitors 2
  • Second-line: Add calcium channel blockers 2
  • Third-line: Add angiotensin receptor blockers 2

Gastrointestinal Manifestations

Small intestinal bacterial overgrowth (SIBO):

  • Recommended: Rotating antibiotics (confirmed by breath testing) 1

Esophageal dysmotility:

  • Proton pump inhibitors for reflux
  • Prokinetic agents (prucalopride for constipation) 1

Inflammatory Arthritis

Treatment sequence (79% expert agreement):

  • First-line: Methotrexate 2
  • Second-line: Low-dose glucocorticoids 2
  • Third-line: Hydroxychloroquine 2
  • Fourth-line: Rituximab or tocilizumab 2

Critical Practice Points

Avoid these pitfalls:

  1. Do not delay immunosuppression in progressive skin or lung disease - early intervention with MMF improves outcomes 1
  2. Do not use monotherapy for severe PAH - combination therapy is now standard for newly diagnosed cases 1
  3. Do not overlook non-pharmacological management - physical exercise improves fatigue, aerobic capacity, and functional outcomes 3
  4. Do not treat all skin involvement the same - tocilizumab is specifically for early, inflammatory dcSSc, not established fibrosis 1

Emerging Therapies

Recent guidelines now include first-ever recommendations for biologics in SSc: rituximab and tocilizumab for skin fibrosis represent a paradigm shift from purely immunosuppressive approaches 1. Current practice shows 85% of specialists have prescribed rituximab and 65% tocilizumab for dcSSc without ILD 5.

Multidisciplinary Approach

SSc management requires coordination between rheumatology, pulmonology, cardiology, and gastroenterology given the multi-organ nature of disease 6. Regular screening for organ involvement is essential, though specific screening protocols warrant individualized assessment based on disease subset and antibody profile 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.